Karyopharm Therapeutics’ (KPTI) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

A number of other analysts have also recently issued reports on the company. Piper Sandler increased their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock opened at $0.64 on Wednesday. Karyopharm Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $1.95. The company’s 50 day simple moving average is $0.75 and its 200 day simple moving average is $0.81.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the business posted ($0.30) EPS. Equities research analysts predict that Karyopharm Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics in the second quarter worth $167,000. Point72 DIFC Ltd acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $31,000. Cubist Systematic Strategies LLC bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $494,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $143,000. Finally, AQR Capital Management LLC grew its holdings in shares of Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after acquiring an additional 622,194 shares in the last quarter. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).